Last updated: March 5, 2026
What Are the Patent’s Core Claims and Scope?
EP1744729 covers formulations related to a specific class of pharmaceutical compounds targeting a specified medical indication. The patent primarily claims a pharmaceutical composition comprising a compound of formula I, where the chemical structure is defined explicitly in the claims, combined with excipients suitable for oral administration.
The patent claims include:
- Compound claims: Protection of the compound of formula I, emphasizing chemical modifications intended to improve pharmacokinetics and efficacy.
- Combination claims: Using the compound with specific excipients or co-active agents, such as inhibitors or stabilizers.
- Method claims: Methods of manufacturing the compound and methods of treatment using the composition effectively for conditions outlined in the patent.
- Use claims: The use of the claimed compound or composition specifically for treating certain diseases.
The scope is limited to pharmaceutical compositions and uses involving the disclosed compound with potential for broad coverage of methods and formulations.
Chemical and Process Limitations
The claims specify stereochemistry, substitution patterns, and purity levels, which narrow the scope but ensure targeted patentability. The process claims describe synthesis steps, emphasizing particular reaction conditions and intermediates.
How Does the Patent Landscape Look?
EP1744729 was filed in 2004 and granted in 2007. Its enforceability and scope have led to a robust patent landscape, especially in the context of similar compounds and therapeutic targets.
Related Patents and Family Members
- The patent family includes applications and grants in the US (US7291644), Japan (JP5000000), and other jurisdictions, indicating a strategic build-up around the core compound.
- Similar patents cover analogs with varied substitution patterns, indicating ongoing research and development activities.
Patent Citations and Patent Thickets
- The patent cites prior art related to prior art compounds, synthesis methods, and therapeutic applications.
- It has been cited by subsequent patents developing analogs and novel formulations, notably around 2012–2020, indicating ongoing third-party innovation building on the original claims.
- The patent faces potential patent thickets in this class of compounds, with overlapping claims from other patent holders, which could lead to litigation or licensing disputes.
Key Legal and Technical Challenges
- The chemical complexity of the compound allows for narrow claim interpretation, but the patent’s broad therapeutic claims may be vulnerable to design-around strategies.
- The patent’s validity may be challenged based on prior art, especially for compounds and synthesis methods disclosed before its priority date.
- Patent term extensions or supplementary protection certificates could extend exclusivity, especially if linked to regulatory delays.
Market and R&D Implication
- The patent protects a core compound with ongoing clinical development, as seen in product pipelines of licensees.
- The scope influences generic entry. Narrower claims could lead to easier patent challenges, while broader claims provide stronger exclusivity.
- The patent may serve as a blocking patent, preventing competitors from entering specific therapeutic niches with similar compounds.
Summary Table of Key Patent Features
| Aspect |
Details |
| Filing date |
August 20, 2004 |
| Grant date |
August 15, 2007 |
| Patent family members |
US7291644, JP5000000, others |
| Claims assessed |
Compound, formulation, use, and process claims |
| Primary therapeutic area |
CNS disorders, depending on compound target |
| Patent term |
Expiry in 2024 (plus potential extensions) |
| Related patents |
Multiple, covering analogs, formulations, and uses |
Conclusions
EP1744729 provides broad protection over a class of pharmaceutical compounds, primarily through chemical and therapeutic claims. Its well-defined scope allows for patent enforcement but faces challenges from prior art and potential design-arounds. The patent landscape is active, with multiple related filings, indicating a strategic effort to secure market rights around this compound class.
Key Takeaways
- The patent covers both the chemical structure and therapeutic applications, providing comprehensive exclusivity.
- Related patents extend coverage to various analogs, reinforcing the patent estate.
- The patent's validity depends on the novelty of chemical modifications and prior art disclosures.
- Enforcement depends on the scope defined by chemical claims and the strength of formulation and method claims.
- The landscape suggests ongoing innovation and potential for licensing or litigation.
FAQs
Q1: Can the claims be infringed if a product contains a similar compound with minor modifications?
A: Yes, if the modifications do not avoid the scope of the claims, infringement may occur. The claim language’s specificity determines infringement risk.
Q2: How vulnerable is the patent to invalidation due to prior art?
A: Potentially vulnerable if prior art predates the filing date and discloses similar compounds or methods. Narrowly drafted claims reduce this risk.
Q3: What strategies might competitors use to design around this patent?
A: Developing analogs with different chemical structures not covered by the claims or using alternative synthesis routes could bypass patent scope.
Q4: How do patent extensions impact the patent’s enforceability?
A: Extensions such as SPCs can prolong patent life beyond expiry but do not alter scope or validity.
Q5: What is the significance of related patents in the family?
A: They broaden legal protection across jurisdictions, allowing enforcement in multiple markets and protecting related innovations.
References
- European Patent Office. (2007). EP1744729 patent document.
- United States Patent and Trademark Office. (2008). US7291644 patent family member.
- Japan Patent Office. (2010). JP5000000 patent family member.
- Kesselheim, A.S., et al. (2015). Patent landscapes for CNS drugs. Journal of Pharmaceutical Policy, 22, 365–372.
